Emergent BioSolutions Inc.
EBS
$8.07
-$0.06-0.74%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -28.81% | -29.91% | -22.74% | -18.56% | -0.54% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -28.81% | -29.91% | -22.74% | -18.56% | -0.54% |
| Cost of Revenue | -48.66% | -50.77% | -49.99% | -11.73% | -7.80% |
| Gross Profit | 17.90% | 26.74% | 80.01% | -31.00% | 22.09% |
| SG&A Expenses | -37.53% | -38.34% | -29.56% | -22.77% | -16.26% |
| Depreciation & Amortization | 0.00% | 0.15% | 0.15% | 0.62% | -0.76% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -42.72% | -44.81% | -42.16% | -14.38% | -9.99% |
| Operating Income | 324.03% | 255.85% | 171.84% | -510.00% | 69.18% |
| Income Before Tax | 157.94% | 162.37% | 132.99% | 88.85% | 80.46% |
| Income Tax Expenses | -36.69% | -23.08% | 475.28% | 919.12% | 62.80% |
| Earnings from Continuing Operations | 127.60% | 136.35% | 123.76% | 76.72% | 74.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 127.60% | 136.35% | 123.76% | 76.72% | 74.94% |
| EBIT | 324.03% | 255.85% | 171.84% | -510.00% | 69.18% |
| EBITDA | 286.85% | 645.76% | 495.99% | -49.92% | 216.63% |
| EPS Basic | 126.18% | 135.32% | 123.23% | 76.89% | 75.68% |
| Normalized Basic EPS | 189.54% | 185.16% | 154.97% | 66.67% | 56.71% |
| EPS Diluted | 122.42% | 131.63% | 121.77% | 75.41% | 74.97% |
| Normalized Diluted EPS | 178.61% | 176.10% | 151.41% | 56.08% | 55.04% |
| Average Basic Shares Outstanding | 0.99% | 2.96% | 3.55% | 3.73% | 3.67% |
| Average Diluted Shares Outstanding | 2.70% | 4.66% | 6.14% | 6.34% | 4.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |